Angion is a clinical stage biopharmaceutical company focused on acute kidney injury, a potentially life-threatening condition without therapeutic options. Our lead clinical asset, ANG-3777, is engineered to activate the HGF/c-MET pathway, an important mechanism in organ repair. Angion is developing ANG-3777 to meet the high unmet medical need of acute kidney injury resulting from kidney transplantation and from cardiac surgery. We are currently conducting Phase 2 and Phase 3 clinical trials with improvement in kidney function as an endpoint. Angion’s robust pipeline includes ANG-3070, an oral small molecule in development as a potential treatment for fibrosis and other severe organ damage.